The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Open accessAbstract
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors express the estrogen receptor (ER). Tamoxifen and aromatase inhibitors (AIs) are the most common and effective therapies for patients with ERα-positive breast cancer. Alone or combined with chemotherapy, tamoxifen significantly reduces disease progression and is associated with more favorable impact on survival in patients. Unfortunately, endocrine resistance occurs, either de novo or acquired during the course of the treatment. The mechanisms that contribute to hormonal resistance include loss or modification in the ERα expression, regulation of signal transduction pathways, altered expression of specific microRNAs, balance of co-regulatory proteins, and genetic polymorphisms involved in tamoxifen metabolic activity. Because of the clinical consequences of endocrine resistance, new treatment strategies are arising to make the cells sensitive to tamoxifen. Here, we will review the current knowledge on mechanisms of endocrine resistance in breast cancer cells. In addition, we will discuss novel therapeutic strategies to overcome such resistance. Undoubtedly, circumventing endocrine resistance should help to improve therapy for the benefit of breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zhao, J.-J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., Coppola, D., & Cheng, J. Q. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806041200 · Cited by 509
RetractedWong, C.-W., McNally, C., Nickbarg, E., Komm, B. S., & Cheskis, B. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192569699 · Cited by 324
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
The stress-activated protein kinase subfamily of c-Jun kinases
Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., & Woodgett, J. R. (1994) · Nature · doi:10.1038/369156a0 · Cited by 2,596
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A
Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.-M., Argos, P., & Chambon, P. (1986) · Nature · doi:10.1038/320134a0 · Cited by 2,321
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., & Meltzer, P. S. (1997) · Science · doi:10.1126/science.277.5328.965 · Cited by 1,639
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436
Identity of an Estrogen Membrane Receptor Coupled to a G Protein in Human Breast Cancer Cells
Thomas, P., Pang, Y., Filardo, E. J., & Dong, J. (2005) · Endocrinology · doi:10.1210/en.2004-1064 · Cited by 1,407
Filardo, E. J. (2000) · Molecular Endocrinology · doi:10.1210/me.14.10.1649 · Cited by 1,383
Estrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,320
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Functional domains of the human estrogen receptor
Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.-R., & Chambon, P. (1987) · Cell · doi:10.1016/0092-8674(87)90581-2 · Cited by 1,316
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis
Kosaka, N., Iguchi, H., & Ochiya, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01650.x · Cited by 1,147
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
Rountree, M. R., Bachman, K. E., & Baylin, S. B. (2000) · Nature Genetics · doi:10.1038/77023 · Cited by 1,052
The human estrogen receptor has two independent nonacidic transcriptional activation functions
Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E., & Chambon, P. (1989) · Cell · doi:10.1016/0092-8674(89)90031-7 · Cited by 1,048
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Bunone, G., Briand, P. A., Miksicek, R. J., & Picard, D. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00571.x · Cited by 986
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 959
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Robertson, K. D., Ait-Si-Ali, S., Yokochi, T., Wade, P. A., Jones, P. L., & Wolffe, A. P. (2000) · Nature Genetics · doi:10.1038/77124 · Cited by 942
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Filardo, E. J., Quinn, J. A., Frackelton, A. R., & Bland, K. I. (2002) · Molecular Endocrinology · doi:10.1210/me.16.1.70 · Cited by 904
Frasor, J., Danes, J. M., Komm, B., Chang, K. C. N., Lyttle, C. R., & Katzenellenbogen, B. S. (2003) · Endocrinology · doi:10.1210/en.2003-0567 · Cited by 876
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Constitutive Activation of NF-κB during Progression of Breast Cancer to Hormone-Independent Growth
Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., & Sledge, G. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3629 · Cited by 819
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
Berry, M., Metzger, D., & Chambon, P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07469.x · Cited by 767
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells
Dontu, G., Jackson, K. W., McNicholas, E., Kawamura, M. J., Abdallah, W. M., & Wicha, M. S. (2004) · Breast Cancer Research · doi:10.1186/bcr920 · Cited by 762
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., & Majumder, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804612200 · Cited by 749
Characterization of the Structure and Function of a New Mitogen-activated Protein Kinase (p38β)
Jiang, Y., Chen, C., Li, Z., Guo, W., Gegner, J. A., Lin, S., & Han, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17920 · Cited by 746
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., & Sonenshein, G. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119848 · Cited by 720
Webb, P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.4.443 · Cited by 693
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
Smith, C. S., Nawaz, Z., & O’Malley, B. W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.657 · Cited by 662
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660 · cited 1×
“In a xenograft model for human breast cancer, NCoR levels decreased in the tumors that acquired resistance to tamoxifen [230].”
BackgroundMechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 642
Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M., Bilancio, A., Lombardi, M., Gong, W., Beato, M., & Auricchio, F. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.2008 · Cited by 626
Carmeci, C., Thompson, D. A., Ring, H. Z., Francke, U., & Weigel, R. J. (1997) · Genomics · doi:10.1006/geno.1997.4972 · Cited by 591
Clark, A. S., West, K. A., Streicher, S. A., & Dennis, P. A. (2002) · PubMed · Cited by 589
Cytochrome P450 pharmacogenetics and cancer
Rodriguez-Antona, C., & Ingelman-Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 575
Aberrant Activation of Notch Signaling in Human Breast Cancer
Stylianou, S., Clarke, R. B., & Brennan, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3054 · Cited by 562
Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H., Glass, C. K., & Rosenfeld, M. G. (2002) · Cell · doi:10.1016/s0092-8674(02)00809-7 · Cited by 558
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Kumar, V., Green, S., Staub, A., & Chambon, P. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04489.x · Cited by 530
Estrogen receptor interaction with co-activators and co-repressors☆
Klinge, C. M. (2000) · Steroids · doi:10.1016/s0039-128x(99)00107-5 · Cited by 491
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
Ottaviano, Y. L., Issa, J. J., Parl, F. F., Smith, H. S., Baylin, S. B., & Davidson, N. E. (1994) · PubMed · Cited by 481
Adams, B. D., Furneaux, H., & White, B. A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0022 · Cited by 478
Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway
Kahlert, S., Nuedling, S., van Eickels, M., Vetter, H., Meyer, R., & Grohé, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910345199 · Cited by 474
Proximal Events in Signaling by Plasma Membrane Estrogen Receptors
Razandi, M., Pedram, A., Park, S. T., & Levin, E. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205692200 · Cited by 473
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger, P., Sahla, M. E., Mäkelä, S., Gustafsson, J. A., Baldet, P., & Rochefort, H. (2001) · PubMed · Cited by 471
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., & Osborne, C. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031212 · Cited by 462
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
Angel, P., & Karin, M. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(91)90011-9 · Cited by 450
AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor
Font de Mora, J., & Brown, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5041-5047.2000 · Cited by 432
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Howell, A., Robertson, J. F. R., Abram, P., Lichinitser, M. R., Elledge, R., Bajetta, E., Watanabe, T., Morris, C., Webster, A., Dimery, I., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.112 · Cited by 421
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2702 · Cited by 407
Razandi, M. (2002) · Molecular Endocrinology · doi:10.1210/me.16.1.100 · Cited by 402
Estrogen Receptor Mutations in Human Disease
Herynk, M. H., & Fuqua, S. A. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0010 · Cited by 400
Selective Estrogen Receptor Modulators
Frasor, J., Stossi, F., Danes, J. M., Komm, B., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 395
Clark, G. M., Osborne, C. K., & McGuire, W. L. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.10.1102 · Cited by 392
Oestrogen receptors – an overview
Enmark, E., & Gustafsson, J. ‐. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00545.x · Cited by 380
Foekens, J. A., Sieuwerts, A. M., Smid, M., Look, M. P., de Weerd, V., Boersma, A. W. M., Klijn, J. G. M., Wiemer, E. A. C., & Martens, J. W. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803304105 · Cited by 370
Kurokawa, H., Lenferink, A. E. G., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., & Arteaga, C. L. (2000) · PubMed · Cited by 363
Filardo, E. J., Graeber, C. T., Quinn, J. A., Resnick, M. B., Giri, D., DeLellis, R. A., Steinhoff, M. M., & Sabo, E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0860 · Cited by 361
Sun, M., Paciga, J. E., Feldman, R. I., Yuan, Z., Coppola, D., Lu, Y., Shelley, S. A., Nicosia, S. V., & Cheng, J. Q. (2001) · PubMed · Cited by 360
Estrogen receptor and breast cancer
Sommer, S., & Fuqua, S. A. W. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0389 · Cited by 355
Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications
Osborne, C. K., & Schiff, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.036 · Cited by 351
pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167
Joel, P. B., Smith, J., Sturgill, T. W., Fisher, T. L., Blenis, J., & Lannigan, D. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.1978 · Cited by 345
Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P. (2011) · Oncogene · doi:10.1038/onc.2010.487 · Cited by 342
Rizzo, P., Miao, H., D'Souza, G., Osipo, C., Yun, J., Zhao, H., Mascarenhas, J., Wyatt, D., Antico, G., Hao, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5744 · Cited by 341
Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan, V. C., & O'Malley, B. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3886 · Cited by 324
Widschwendter, M., Siegmund, K. D., Müller, H. M., Fiegl, H., Marth, C., Müller-Holzner, E., Jones, P. A., & Laird, P. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3852 · Cited by 324
CYP2D6 and tamoxifen: DNA matters in breast cancer
Hoskins, J. M., Carey, L. A., & McLeod, H. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2683 · Cited by 322
Nuclear-Receptor Ligands and Ligand-Binding Domains
Weatherman, R. V., Fletterick, R. J., & Scanlan, T. S. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.559 · Cited by 322
Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen
Hurtado, A., Holmes, K. A., Geistlinger, T. R., Hutcheson, I. R., Nicholson, R. I., Brown, M., Jiang, J., Howat, W. J., Ali, S., & Carroll, J. S. (2008) · Nature · doi:10.1038/nature07483 · Cited by 321
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
Masamura, S. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.10.2918 · Cited by 307
Nowell, S. A., Ahn, J., Rae, J. M., Scheys, J. O., Trovato, A., Sweeney, C., MacLeod, S. L., Kadlubar, F. F., & Ambrosone, C. B. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-7751-x · Cited by 306
Cloning of the human oestrogen receptor cDNA
Green, S., Walter, P., Greene, G., Krust, A., Goffin, C., Jensen, E., Scrace, G., Waterfield, M., & Chambon, P. (1986) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(86)90035-x · Cited by 302
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
miR-206 Expression Is Down-regulated in Estrogen Receptor α–Positive Human Breast Cancer
Kondo, N., Toyama, T., Sugiura, H., Fujii, Y., & Yamashita, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0180 · Cited by 298
Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 291
Brasher, B. B., & Van Etten, R. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005401200 · Cited by 278
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
Fuqua, S. A. W., Wiltschke, C., ZHANG, Q. X., Borg, Å., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S. G., Mohsin, S. K., O'Connell, P., et al. (2000) · PubMed · Cited by 278
MicroRNA-301 Mediates Proliferation and Invasion in Human Breast Cancer
Shi, W., Gerster, K., Alajez, N. M., Tsang, J., Waldron, L., Pintilie, M., Hui, A. B., Sykes, J., P'ng, C., Miller, N., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3369 · Cited by 266
Picard, D., Kumar, V, Chambon, P., & Yamamoto, K. R. (1990) · Cell Regulation · doi:10.1091/mbc.1.3.291 · Cited by 260
Zhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 259
Role of ADAMs in Cancer Formation and Progression
Duffy, M. J., McKiernan, E., O'Donovan, N., & McGowan, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1585 · Cited by 259
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?
Speirs, V., Parkes, A., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., & Atkin, S. L. (1999) · PubMed · Cited by 255
Creighton, C. J., Hilger, A. M., Murthy, S., Rae, J. M., Chinnaiyan, A. M., & El-Ashry, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4363 · Cited by 243
Martin, M. B., Franke, T. F., Stoica, G. E., Chambon, P., Katzenellenbogen, B. S., Stoica, B. A., McLemore, M. S., Olivo, S. E., & Stoica, A. (2000) · Endocrinology · doi:10.1210/endo.141.12.7836 · Cited by 231
Iorns, E., Turner, N. C., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230
Kurebayashi, J., Otsuki, T., Kunisue, H., Tanaka, K., Yamamoto, S., & Sonoo, H. (2000) · PubMed · Cited by 226
Role for c-Abl tyrosine kinase in growth arrest response to DNA damage
Yuan, Z.-M., Huang, Y., Whang, Y., Sawyers, C., Weichselbaum, R., Kharbanda, S., & Kufe, D. (1996) · Nature · doi:10.1038/382272a0 · Cited by 218
Rothé, F., Ignatiadis, M., Chaboteaux, C., Haibe-Kains, B., Kheddoumi, N., Majjaj, S., Badran, B., Fayyad-Kazan, H., Desmedt, C., Harris, A. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020980 · Cited by 217
Function of the IGF-I Receptor in Breast Cancer
Surmacz, E. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009523501499 · Cited by 214
Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo
Schiff, R. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211
Mitra, D., Brumlik, M. J., Okamgba, S. U., Zhu, Y., Duplessis, T. T., Parvani, J. G., Lesko, S. M., Brogi, E., & Jones, F. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0295 · Cited by 204
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
Shao, W., & Brown, M. (2003) · Breast Cancer Research · doi:10.1186/bcr742 · Cited by 203
Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
Zhou, Y., Yau, C., Gray, J. W., Chew, K., Dairkee, S. H., Moore, D. H., Eppenberger, U., Eppenberger-Castori, S., & Benz, C. C. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-59 · Cited by 203
Joel, P. B., Traish, A. M., & Lannigan, D. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13317 · Cited by 202
Lee, H., & Bai, W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5835-5845.2002 · Cited by 202
Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer
Hopp, T. A., Weiss, H. L., Parra, I. S., Cui, Y., Osborne, C. K., & Fuqua, S. A. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1114 · Cited by 197
Estrogen receptor: current understanding of its activation and modulation.
Osborne, C. K., Schiff, R., Fuqua, S. A. W., & Shou, J. (2001) · PubMed · Cited by 194
Girault, I., Lerebours, F., Amarir, S., Tozlu, S., Tubiana-Hulin, M., Lidereau, R., & Bièche, I. (2003) · PubMed · Cited by 193
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Cittelly, D. M., Das, P. M., Spoelstra, N. S., Edgerton, S. M., Richer, J. K., Thor, A. D., & Jones, F. E. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-317 · Cited by 191
Knowlden, J. M., Hutcheson, I. R., Barrow, D., Gee, J. M. W., & Nicholson, R. I. (2005) · Endocrinology · doi:10.1210/en.2005-0247 · Cited by 188
Lo, P.-K., & Sukumar, S. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1879 · Cited by 184
Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., Lin, L., & Ellis, M. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2833 · Cited by 184
Estrogen receptor beta expression in invasive breast cancer
Mann, S., Laucirica, R., Carlson, N., Younes, P. S., Ali, N., Younes, A., Li, Y., & Younes, M. (2001) · Human Pathology · doi:10.1053/hupa.2001.21506 · Cited by 183
Epigenetic Information and Estrogen Receptor Alpha Expression in Breast Cancer
Giacinti, L., Claudio, P. P., Lopez, M., & Giordano, A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-1-1 · Cited by 183
Bergamaschi, A., & Katzenellenbogen, B. S. (2012) · Oncogene · doi:10.1038/onc.2011.223 · Cited by 181
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Dibb, N. J., Dilworth, S. M., & Mol, C. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1434 · Cited by 179
Neal, C. L., Yao, J., Yang, W., Zhou, X., Nguyen, N. T., Lu, J., Danes, C. G., Guo, H., Lan, K.-H., Ensor, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2765 · Cited by 175
Zhang, Y., Moerkens, M., Ramaiahgari, S., de Bont, H., Price, L., Meerman, J., & van de Water, B. (2011) · Breast Cancer Research · doi:10.1186/bcr2883 · Cited by 171
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.
Dowsett, M. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080191 · Cited by 171
Miller, T. W., Pérez-Torres, M., Narasanna, A., Guix, M., Stål, O., Pérez-Tenorio, G., Gonzalez-Angulo, A. M., Hennessy, B. T., Mills, G. B., Kennedy, J. P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0042 · Cited by 168
The p38 MAP Kinase Pathway and Its Biological Function
New, L., & Han, J. (1998) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(98)00012-7 · Cited by 164
Howell, A., Pippen, J., Elledge, R. M., Mauriac, L., Vergote, I., Jones, S. E., Come, S. E., Osborne, C. K., & Robertson, J. F. R. (2005) · Cancer · doi:10.1002/cncr.21163 · Cited by 163
Frasor, J., Chang, E. C., Komm, B., Lin, C.-Y., Vega, V. B., Liu, E. T., Miller, L. D., Smeds, J., Bergh, J., & Katzenellenbogen, B. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4269 · Cited by 162
Xiong, J., Yu, D., Wei, N., Fu, H., Cai, T., Huang, Y., Wu, C., Zheng, X., Du, Q., Lin, D., et al. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07594.x · Cited by 160
Nowell, S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.21.1635 · Cited by 160
Sabnis, G. J., Goloubeva, O., Chumsri, S., Nguyen, N., Sukumar, S., & Brodie, A. M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2458 · Cited by 158
Wolf, D. M., & Jordan, V. C. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689683 · Cited by 155
Johnston, S. R. D., Lü, B., Scott, G. K., Kushner, P. J., Smith, I. E., Dowsett, M., & Benz, C. C. (1999) · PubMed · Cited by 153
Keen, J. C., Lan, Y., Mack, K. M., Pettit, C., Smith, D., Sharma, D., & Davidson, N. E. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1026146524737 · Cited by 151
Britton, D. J., Hutcheson, I. R., Knowlden, J. M., Barrow, D., Giles, M. G., McClelland, R. A., Gee, J. M. W., & Nicholson, R. I. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9070-2 · Cited by 151
Chan, C. M. W., Martin, L., Johnston, S. R. D., Ali, S., & Dowsett, M. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00074-2 · Cited by 149
Altered expression of estrogen receptor coregulators during human breast tumorigenesis.
Murphy, L. C., Simon, S. L., Parkes, A., et al. (2000) · PubMed · Cited by 149
Cittelly, D. M., Das, P. M., Salvo, V. A., Fonseca, J. P., Burow, M. E., & Jones, F. E. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq192 · Cited by 149
Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue
List, H.-J., Reiter, R., Singh, B., Wellstein, A., & Riegel, A. T. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1017910924390 · Cited by 148
Molecular and pharmacological aspects of antiestrogen resistance
Clarke, R. C., Skaar, T. C., Bouker, K. B., Davis, N., Lee, Y. R., Welch, J. N., & Leonessa, F. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00193-x · Cited by 144
Chung, Y., Sheu, M., Yang, S., Lin, C., & Yen, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1614 · Cited by 142
Macaluso, M., Cinti, C., Russo, G. M., Russo, A. D., & Giordano, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206578 · Cited by 137
Crossroads of Estrogen Receptor and NF-κB Signaling
Biswas, D. K., Singh, S., Shi, Q., Pardee, A. B., & Iglehart, J. D. (2005) · Science s STKE · doi:10.1126/stke.2882005pe27 · Cited by 137
Position paper: The membrane estrogen receptor GPER – Clues and questions
Barton, M. (2012) · Steroids · doi:10.1016/j.steroids.2012.04.001 · Cited by 131
Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0354-x · Cited by 129
Jansen, M. P. H. M., Sieuwerts, A. M., Look, M. P., Ruigrok-Ritstier, K., Gelder, M. E. M., van Staveren, I. L., Klijn, J. G. M., Foekens, J. A., & Berns, E. M. J. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3676 · Cited by 129
Santen, R. J., Song, R., Zhang, Z., Kumar, R., Jeng, M. H., Masamura, A., Lawrence, J., Berstein, L. M., & Yue, W. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01018 · Cited by 125
Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells
Cui, J., Germer, K., Wu, T., Wang, J., Luo, J., Wang, S., Wang, Q., & Zhang, X. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1305 · Cited by 124
Sabnis, G. J., Schayowitz, A., Goloubeva, O. G., Macedo, L. F., & Brodie, A. M. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0857 · Cited by 123
MicroRNA-101-mediated Akt activation and estrogen-independent growth
Sachdeva, M., Wu, H., Ru, P., Hwang, L., Trieu, V. N., & Mo, Y.-Y. (2010) · Oncogene · doi:10.1038/onc.2010.463 · Cited by 123
Xin, F., Li, M., Balch, C., Thomson, M., Fan, M., Liu, Y., Hammond, S. M., Kim, S., & Nephew, K. P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn646 · Cited by 123
Defining a minimal estrogen receptor DNA binding domain
Mader, S., Chambon, P., & White, J. H. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.5.1125 · Cited by 123
Breast cancer and microRNAs: therapeutic impact
Iorio, M. V., Casalini, P., Piovan, C., Braccioli, L., & Tagliabue, E. (2011) · The Breast · doi:10.1016/s0960-9776(11)70297-1 · Cited by 121
Fagan, D. H., Uselman, R. R., Sachdev, D., & Yee, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0684 · Cited by 118
Identification of a Third Autonomous Activation Domain within the Human Estrogen Receptor
Norris, J. D., Fan, D., Kerner, S. A., & McDonnell, D. P. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0008 · Cited by 113
Kirkegaard, T., McGlynn, L. M., Campbell, F., Müller, S., Tovey, S., Dunne, B., Nielsen, K. V., Cooke, T. G., & Bartlett, J. M. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1933 · Cited by 112
Masri, S., Phung, S., Wang, X., Wu, X., Yuan, Y., Wagman, L. D., & Chen, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0303 · Cited by 110
Webster, N. J., Green, S., Tasset, D. M., Ponglikitmongkol, M., & Chambon, P. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03526.x · Cited by 106
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells
Masri, S., Liu, Z., Phung, S., Wang, E., Yuan, Y., & Chen, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0716-3 · Cited by 106
Hypoxia Induces Proteasome-Dependent Degradation of Estrogen Receptor α in ZR-75 Breast Cancer Cells
Stoner, M. A., Saville, B., Wormke, M., Dean, D. D., Burghardt, R. C., & Safe, S. H. (2002) · Molecular Endocrinology · doi:10.1210/me.2001-0347 · Cited by 105
Aesöy, R., Sanchez, B. C., Norum, J. H., Lewensohn, R., Viktorsson, K., & Linderholm, B. K. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2172 · Cited by 105
The interaction between ER and NFκB in resistance to endocrine therapy
Sas, L., Lardon, F., Vermeulen, P. B., Hauspy, J., van Dam, P. A., Pauwels, P., Dirix, L. Y., & Laere, S. V. (2012) · Breast Cancer Research · doi:10.1186/bcr3196 · Cited by 105
Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma
Dhaini, H. R., Thomas, D. G., Giordano, T. J., Johnson, T. D., Biermann, J. S., Leu, K. M., Hollenberg, P. F., & Baker, L. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.015 · Cited by 104
Hurbin, A., Dubrez, L., Coll, J., & Favrot, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207584200 · Cited by 102
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues
Miyoshi, Y., Ando, A., Takamura, Y., Taguchi, T., Tamaki, Y., & Noguchi, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1568 · Cited by 100
Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters
Kiyotani, K., Mushiroda, T., Nakamura, Y., & Zembutsu, H. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-084 · Cited by 100
Luqmani (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.942 · Cited by 99
Klinge, C. M., Riggs, K. A., Wickramasinghe, N. S. M. D., Emberts, C. G., McConda, D. B., Barry, P. N., & Magnusen, J. E. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.03.013 · Cited by 98
Cavazzoni, A., Bonelli, M. A., Fumarola, C., Monica, S. L., Airoud, K., Bertoni, R., Alfieri, R. R., Galetti, M., Tramonti, S., Galvani, E., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.034 · Cited by 94
Thomas, P., Alyea, R. A., Pang, Y., Peyton, C., Dong, J., & Berg, H. (2009) · Steroids · doi:10.1016/j.steroids.2009.11.005 · Cited by 91
Dumont, J. A., Bitonti, A. J., Wallace, C. D., et al. (1996) · PubMed · Cited by 89
Li, M., Li, J., Ding, X.-F., He, M., & Cheng, S.-Y. (2010) · AAPS Journal · doi:10.1208/s12248-010-9194-0 · Cited by 89
Bergamaschi, A., Christensen, B. L., & Katzenellenbogen, B. S. (2011) · Breast Cancer Research · doi:10.1186/bcr2913 · Cited by 89
Leary, A. F., Drury, S., DETRE, S. I., Pancholi, S., Lykkesfeldt, A. E., Martin, L., Dowsett, M., & Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1764 · Cited by 88
Rational management of endocrine resistance in breast cancer
Hurvitz, S. A., & Pietras, R. J. (2008) · Cancer · doi:10.1002/cncr.23875 · Cited by 87
The evolving role of aromatase inhibitors in breast cancer
Mokbel, K. (2002) · International Journal of Clinical Oncology · doi:10.1007/s101470200040 · Cited by 86
Marino, M., & Ascenzi, P. (2008) · Steroids · doi:10.1016/j.steroids.2007.12.003 · Cited by 86
Wang, L., Yang, X. Y., Zhang, X., An, P., Kim, H.-J., Huang, J., Clarke, R. C., Osborne, C. K., Inman, J. K., Appella, E., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.015 · Cited by 83
Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma.
Weigel, R. J., & deConinck, E. C. (1993) · PubMed · Cited by 83
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
Beelen, K. J., Zwart, W. T., & Linn, S. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.121 · Cited by 82
Regulation of estrogen receptor-alpha gene expression by epidermal growth factor
Stoica, A., Saceda, M., Doraiswamy, V., Coleman, C., & Martin, M. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650371 · Cited by 81
Manavalan, T. T., Teng, Y., Appana, S. N., Datta, S., Kalbfleisch, T., Li, Y., & Klinge, C. M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.018 · Cited by 79
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
Buzdar, A. U. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn739 · Cited by 78
Zhou, Q. Y., Shaw, P. G., & Davidson, N. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0148-5 · Cited by 75
Oncogenic K-ras in Mouse Models of Myeloproliferative Disease and Acute Myeloid Leukemia
Chan, I. T., & Gilliland, D. G. (2004) · Cell Cycle · doi:10.4161/cc.3.5.827 · Cited by 75
Arteaga, C. L., Koli, K., Dugger, T. C., & Clarke, R. C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.46 · Cited by 75
Cited by
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R., Rosales-Corral, S., Tan, D.-X., Acuna-Castroviejo, D., Qin, L., Yang, S.-F., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 433
Metadata
- Authors
- García-Becerra, R., Santos, N., Díaz, L., & Camacho, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-12-20
- Volume
- 14
- Issue
- 1
- Pages
- 108-145
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2052631876
- Cited by
- 253
- References
- 236
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.